文献速递腹部MR

钆贝葡胺增强肝胆期胆道成像可预测肝硬化进展

Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.
PubMed 文献 · Eur Radiol · 2021-02-03

单中心回顾性研究纳入270例接受钆贝葡胺增强MRI的患者,测量胆道系统相对强化率(REB)和肝实质相对强化率(REL)。随访38.5±22.5个月,REB是肝硬化患者发生肝功能失代偿和肝功能不全的显著预测因子,REB的AUC分别为0.83和0.82,均优于REL(0.52和0.57)。

要点

  • 肝胆期胆道系统相对强化率(REB)可预测肝硬化患者肝功能失代偿和肝功能不全。
  • REB预测肝功能失代偿AUC 0.83,预测肝功能不全AUC 0.82。
  • 肝实质相对强化率(REL)与上述结局无显著关联,预测价值有限。

诊断标准与关键数值

  • REL预测肝功能失代偿:与肝功能失代偿无关联,AUC=0.52。
  • REL预测肝功能不全:与肝功能不全无统计学显著关联,AUC=0.57。

临床应用与阅片要点

  • 作者结论认为,肝胆期胆道成像对预测肝硬化患者肝功能失代偿和肝功能不全有价值,且REB的预测价值优于REL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine the value of gadobenate dimeglumine (Gd-BOPTA)-enhanced biliary imaging from the hepatobiliary phase in predicting hepatic decompensation and insufficiency for patients with cirrhosis.

METHODS: This single-center retrospective study included 270 patients who underwent Gd-BOPTA-enhanced magnetic resonance imaging. The relative enhancement ratios of the biliary system (REB) and liver parenchyma (REL) in patients with normal liver function without underlying chronic liver disease and three groups of patients with Child-Pugh A, Child-Pugh B, and Child-Pugh C disease were measured. After a mean follow-up of 38.5 ± 22.5 months, prognostic factors were evaluated using the Cox proportional hazards regression model. Receiver operating characteristic (ROC) curve analyses were performed to assess the capacity of the REB and REL to predict the development of hepatic decompensation and insufficiency.

RESULTS: During the follow-up period, nine of 79 patients with Child-Pugh A disease developed hepatic decompensation. The REB was a significant predictive factor (hazard ratio (HR) = 0.40 (0.19-0.84); p = 0.016), but the REL showed no association with hepatic decompensation. Moreover, the areas under the ROC curves (AUCs) were 0.83 and 0.52 for the REB and REL, respectively. Thirty-eight of 207 patients with cirrhosis developed hepatic insufficiency. The REB was a significant predictive factor (HR = 0.24 (0.13-0.46); p < 0.0001), but the REL did not show statistically significant association with hepatic insufficiency. The AUCs were 0.82 and 0.57 for the REB and REL, respectively.

CONCLUSIONS: Gd-BOPTA-enhanced biliary imaging from the hepatobiliary phase was valuable in predicting hepatic decompensation and insufficiency for cirrhotic patients.

KEY POINTS: • Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic decompensation in patients with cirrhosis. • Gd-BOPTA-enhanced biliary imaging was a significant predictive factor for hepatic insufficiency in patients with cirrhosis. • Gd-BOPTA-enhanced biliary imaging showed superior predictive values for adverse clinical outcomes compared to liver parenchymal imaging at the hepatobiliary phase.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Liu C, Sun Y, Yang Y, et al. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis. Eur Radiol. 2021. PMID: 33533990. doi:10.1007/s00330-021-07702-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。